Caremo Granted "Nanjing Municipal Special Dosage Form Drug Engineering Technology Research Center" Certification

June 5, 2023 | Nanjing, China

Caremo has been officially designated as the "Nanjing Municipal Special Dosage Form Drug Engineering Technology Research Center" by the Nanjing Municipal Science and Technology Bureau.

The establishment of Nanjing Municipal Engineering Technology Research Centers is a core initiative under Nanjing’s scientific and technological infrastructure development and a critical component of the city’s regional innovation system. The certification involves stringent procedures, including document review, expert evaluation, and official approval by the municipal authorities. This recognition underscores the Nanjing Municipal Science and Technology Bureau’s acknowledgment of Caremo’s R&D capabilities and innovative strengths, marking a significant milestone in the company’s pharmaceutical research and technological advancement.

Since its inception, Caremo has focused on advancing pharmaceutical research and innovation. Through substantial investments in drug formulation research, the company has established multiple complex dosage form technology platforms, including: · Transdermal drug delivery technology · Sustained/controlled-release formulations · Fixed-dose combination products · Solubility enhancement for poorly soluble drugs · Oral rapid-dissolution technology · Softgel capsule technology These platforms enable Caremo to meet diverse client needs for integrated formulation development services.

Caremo will continue to:

- Strengthen innovative drug R&D technologies

- Deepen technological innovation and industry collaboration

- Accelerate drug development timelines

- Reduce R&D costs Enhance research efficiency

Aligned with its mission—"Born for Health, Empowered for Innovation"—Caremo remains dedicated to advancing China’s pharmaceutical industry through cutting-edge science and sustainable growth.

· About Caremo

Nanjing Caremo Biomedical Co., Ltd., founded in June 2020 by Dr. Zhang Xiaoqing—a National “Ten Thousand Talents Plan” expert and former founder of Huawe Medicine—is headquartered in Nanjing. The company is dedicated to providing global biotech and pharmaceutical enterprises with integrated, customizable R&D solutions, spanning:

- Drug discovery

- Cell biology

- Pharmacology and efficacy studies

- Drug metabolism (DMPK)

- Preclinical safety evaluation

- CMC services

- Clinical trial research

- Customized development

- New drug incubation and investment

Caremo’s end-to-end, tailored solutions and full-cycle project management support partners in accelerating drug development from product initiation to commercialization. The company has assembled a 400+ member R&D team with extensive expertise in preclinical research and CMC (Chemistry, Manufacturing, and Controls). Over 11,000 sqm of chemistry and P2 laboratories compliant with China and U.S. regulatory standards, equipped with hundreds of advanced instruments, are operational. A 35,000 sqm R&D headquarters(with GLP-compliant lab) is currently under construction.

Leveraging its existing platforms, Caremo aims to collaborate with domestic and international biotech and pharmaceutical companies across the entire R&D value chain—from target validation to commercialization. By addressing diverse client needs and embracing flexible partnership models, Caremo will provide a comprehensive, end-to-end drug discovery and production service platform, delivering full-spectrum technological and industrial support to advance global biopharmaceutical innovation.